ProQR Therapeutics (PRQR) Downgraded by ValuEngine

ValuEngine cut shares of ProQR Therapeutics (NASDAQ:PRQR) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday, ValuEngine reports.

Several other equities research analysts have also recently issued reports on the stock. BidaskClub raised shares of ProQR Therapeutics from a sell rating to a hold rating in a research note on Tuesday, April 9th. Zacks Investment Research cut shares of ProQR Therapeutics from a buy rating to a hold rating in a research note on Tuesday, March 19th. Chardan Capital reaffirmed a buy rating and set a $25.00 target price (up previously from $21.00) on shares of ProQR Therapeutics in a research note on Tuesday, March 12th. HC Wainwright reaffirmed a buy rating and set a $20.00 target price on shares of ProQR Therapeutics in a research note on Thursday, February 28th. Finally, Cantor Fitzgerald set a $40.00 target price on shares of ProQR Therapeutics and gave the stock a buy rating in a research note on Tuesday, January 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. ProQR Therapeutics has an average rating of Buy and a consensus target price of $28.67.

Shares of PRQR opened at $12.04 on Friday. ProQR Therapeutics has a 52-week low of $3.20 and a 52-week high of $24.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.28 and a current ratio of 13.28. The firm has a market cap of $508.85 million, a price-to-earnings ratio of -9.33 and a beta of 0.63.

Several hedge funds have recently made changes to their positions in PRQR. Lindbrook Capital LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $25,000. Barclays PLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $51,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $53,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $124,000. Finally, Deutsche Bank AG acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $137,000. 59.44% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Featured Story: Insider Trading – What You Need to Know

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.